Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease.
PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC.
PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC.
Liver Int. 2011 Mar;31(3):348-53. (CUMC Full Text PDF)
It's all about looking good for Canaval. Forget about your liver! This group from Salvador, Brazil studied the prevalence of fatty liver disease in asymptomatic non-competitive male bodybuilders with a history of anabolic-androgenic steroid use. In this case-control study, 12.6% of these athletes met criteria for fatty liver disease, as defined in this study, compared to 2.4% of controls (bodybuilders with no history of anabolic steroid use) (OR=6.0, 95% CI: 1.3-27.6). The authors include anabolic steroid-induced liver disease as a cause of what has been referred to as TAFLD (toxicant-associated fatty liver disease) and TASH (toxicant-associated steatohepatitis).
It's all about looking good for Canaval. Forget about your liver! This group from Salvador, Brazil studied the prevalence of fatty liver disease in asymptomatic non-competitive male bodybuilders with a history of anabolic-androgenic steroid use. In this case-control study, 12.6% of these athletes met criteria for fatty liver disease, as defined in this study, compared to 2.4% of controls (bodybuilders with no history of anabolic steroid use) (OR=6.0, 95% CI: 1.3-27.6). The authors include anabolic steroid-induced liver disease as a cause of what has been referred to as TAFLD (toxicant-associated fatty liver disease) and TASH (toxicant-associated steatohepatitis).
No comments:
Post a Comment